Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility
This article was originally published in The Pink Sheet Daily
Executive Summary
Company faces the possibility of nearly 12 months of limited supply of the rheumatoid arthritis therapy until third-party manufacturer Lonza is approved by FDA, which could occur in mid-2006. Bristol completed the abatacept rolling BLA at the end of March and has requested a priority review.
You may also be interested in...
Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
Firm presents safety, updated pivotal data at European League Against Rheumatism meeting. BLA submission for the first-in-class rheumatoid arthritis biologic was completed in March.
Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
Firm presents safety, updated pivotal data at European League Against Rheumatism meeting. BLA submission for the first-in-class rheumatoid arthritis biologic was completed in March.
Drug Safety Issues Will Raise Regulatory Expectations, Bristol Says
Bristol expects a more critical regulatory environment for its recently submitted muraglitazar NDA. Greater scrutiny by FDA could translate into more focused labeling, CEO Dolan says.